CME Information

Target Audience
 
This activity has been designed to meet the educational needs of cardiologists; diabetologists; primary care physicians (PCPs) including FPs/GPs/IMs; and allied health professionals (nurses, pharmacists, dietitians, NPs, PAs) involved in the care of patients with dyslipidemia, cardiovascular disease, or cardiovascular risk factors.

Statement of Need/Program Overview
 
The care of patients with cardiovascular disease (CVD) and/or diabetes is complex, and determining the best practices for these patients is an ongoing process. Therefore, it is paramount that physicians caring for these patients continue to receive education from lead researchers and clinicians in order to interpret the latest findings, implement best practices, and maximize patient outcomes. This activity will discuss recent advances in high-density lipoprotein-cholesterol complex (HDL-C) and review evidence for HDL-C as a therapeutic target to reduce the residual risk typical in statin-treated high-risk cardiovascular patients. Expert faculty presenters will include their perspectives and interpretations of emerging clinical trial data regarding the management of patients with low HDL-C.

Program Co Chairs: Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA and H. Bryan Brewer, Jr., MD

This activity consists of 2 interviews that interpret and provide clinical application of the most relevant and exciting data on HDL-C coming out of AHA 2011, primarily focusing on the AIM-HIGH and SATURN studies.

Educational Objectives:
After completing this activity, the participant should be better able to:

1. Summarize recent clinical trial data (AIM-HIGH and SATURN) related to therapeutic agents used in the treatment of patients with low HDL-C

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER), Residual Risk Reduction Initiative (R3i), and Consensus Medical Communications (CMC). MER is accredited by the ACCME to provide continuing medical education for physicians. To contact Medical Education Resources please call 303.798.9682.

Credit Designation for "Hot Topics in HDL-From Orlando 2011"
Medical Education Resources designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Medical Education Resources insures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality CME activities that promote improvements or quality in health care and not the business interest of a commercial interest. Faculty disclosures are listed on the Presenter Information page.

Medical Education Resources Privacy Policy
Medical Education Resources, Residual Risk Reduction Initiative, and Consensus Medical Communications maintain high standards for the protection of privacy over the Internet. The purpose of this statement is to explain what information we obtain, how it is used, and how visitors can restrict its use or disclosure.

The only information Medical Education Resources obtains is information supplied voluntarily by the visitor.

We do not sell or disclose individually identifiable information obtained online unless it is required by law or disclosure is necessary to protect the safety of customers, employees, or property.

We use the information to grade your posttest and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your posttest and issue certificates of completion, we will give the information to that company for that purpose only.

For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.

We may use the information to invite you to participate in other CME activities that we may offer.

On occasion, the commercial supporter of a CME activity will ask us for a list of the people who participated in that activity in order to document the first level of outcomes-based evaluation in CME (eg, who attended, which medical specialties/practices were represented, how this compares with the target audience, and whether the activity needs to be repeated because significant numbers of the target audience did not attend). In that event, we will request in writing that the supporter not contact you directly for any purpose.

Medical Education Resources is committed to safeguarding customer privacy, and we require our employees to protect the privacy of information about our customers. Should you wish to delete your information from our files or discuss our privacy policy, please contact us at info@cmepartner.org.

Presenter Information

Chair

Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA Director, Cardiometabolic Disorders Mount Sinai Heart Professor of Medicine Mount Sinai School of Medicine New York, New York

Robert S. Rosenson, MD, FACC, FAHA, FACP, is the director of cardiometabolic disorders at Mount Sinai Heart Institute and professor of medicine at Mount Sinai School of Medicine in New York. Previously, he was the division chief of endocrinology, diabetes, and metabolism at SUNY Downstate Medical Center in Brooklyn, New York. Prior to his time in New York, Dr. Rosenson was the director of lipoprotein disorders and clinical atherosclerosis research and professor of medicine at the University of Michigan School of Medicine in Ann Arbor and an attending physician in the Department of Medicine of the University of Michigan Health System.

Dr. Rosenson earned his medical degree from Tulane University in New Orleans, Louisiana. He then served his residency in medicine at Brigham and Women’s Hospital in Boston, Massachusetts. He later completed a fellowship in cardiology at the University of Chicago.

Dr. Rosenson has been involved in numerous grant-supported research investigations studying the effects of lipid-lowering therapy, hypoglycemic therapy, and antihypertensive agents in inflammation, thrombogenesis, and rheology. He has served as Principal Investigator on a number of National Institutes of Health (NIH)-funded research studies, pharmaceutical-sponsored drug trials, and multicenter studies. He has been an invited speaker at more than 150 national and international association meetings, grand rounds, and symposia. He has authored more than 600 journal articles, book chapters, abstracts, and electronic publications.

Dr. Rosenson is a diplomate of the American Board of Internal Medicine, with a subspecialty in cardiovascular disease; the National Board of Medical Examiners; and the National Lipid Association. He currently serves on a number of committees for professional societies and as a member of the Program Committee and Expert Document Committee for the American College of Cardiology. He is a fellow of the American Heart Association Council on Epidemiology and Prevention, and he is a fellow of the American Heart Association Council on Arteriosclerosis, Thrombosis, and Vascular Biology. He has been the recipient of a number of awards and honors, including the Ground-Breaking Doctors Award from Chicago Magazine.

Faculty Disclosure:

Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA, reports receiving consulting fees from Abbott, Genentech/Roche, Daiichi, Sankyo, Grain Food Board, sanofi-aventis, Residual Risk Reduction Initiative Foundation, and LipoScience. He also reports ownership interest in LipoScience.

Co-chair

H. Bryan Brewer, Jr., MD Director, Washington Cardiovascular Associates Senior Scientific Consultant Cardiovascular Research Institute Medstar Washington, DC

H. Bryan Brewer, Jr., MD, is Director, Washington Cardiovascular Associates and Senior Research Consultant, Lipoprotein and Atherosclerosis Research, Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington, DC. From 1976 to 2005, he held the position of Chief of the Molecular Disease Branch of the National Heart, Lung, and Blood Institute (NHLBI) of the NIH, Bethesda, Maryland.

Dr. Brewer earned his Bachelor of Science from Johns Hopkins University and his Doctorate of Medicine from Stanford University School of Medicine. He completed his internship and residency training in internal medicine at Massachusetts General Hospital in Boston, Massachusetts, after which he joined the NHLBI of the NIH, Bethesda, Maryland.

Dr. Brewer’s research led to the elucidation of the first published sequences for the human plasma apolipoproteins, the initial determination of the metabolism of the plasma apolipoproteins in normal and hyperlipidemic individuals, as well as the identification of multiple gene defects leading to the genetic dyslipoproteinemias. In addition, he pioneered the use of transgenic mice and rabbits, as well as recombinant adenovirus vectors to identify genes that modulate lipoprotein metabolism and the development of atherosclerosis. Most recently, his research has focused on acute HDL therapy employing HDL infusions to decrease atherosclerosis in patients with acute coronary syndrome.

Dr. Brewer has been the recipient of the JD Lane Investigator Award from the Public Health Service, the Heinrich Wieland Prize from the Federal Republic of Germany, and the Public Health Service Commendation, Meritorious Service and Distinguished Service Medals from the NIH. He has served as a member of the board of the National Cholesterol Education Program, which established treatment guidelines for patients with hyperlipidemia in the United States. He has published more than 400 original reports and 70 reviews and book chapters on the subjects of genetic dyslipoproteinemias, lipoprotein metabolism, and atherosclerosis.

Faculty Disclosure:

H. Bryan Brewer, Jr., MD, reports he has served as a consultant for Eli Lilly, Merck/Schering-Plough, Roche/Genentech, and sanofi-aventis.

Faculty

Philip J. Barter, MBBS, PhD, FRACP Director, The Heart Research Institute Sydney, Australia Professor of Medicine University of Sydney, Australia

Philip J. Barter, MBBS, PhD, FRACP, is director of The Heart Research Institute, in Sydney, Australia and also a professor of medicine at the University of Sydney. He graduated in medicine from the University of Adelaide and gained his PhD from the Australian National University. He is a fellow of the Royal Australasian College of Physicians. Currently president elect of the International Atherosclerosis Society, he also is a member of the International Task Force for the Prevention of Coronary Heart Disease and is an executive member of the International Chair on Cardiometabolic Risk. He is the 2011 recipient of the Anitschkow Award of the European Atherosclerosis Society.

Professor Barter has held positions previously in research institutes and universities in Australia and the United States. His basic research interests are plasma lipids and lipoproteins, specifically high-density lipoproteins, the factors that regulate them, and the mechanism by which they protect against cardiovascular disease. His clinical research involves participation in clinical trials of lipid-lowering agents.

Professor Barter was a member of the steering committees of the FIELD study and the TNT Study and was co-chair of the steering committee of the DEFINE study. He also was chairman of the steering committee of the ILLUMINATE trial. He currently is a member of the steering committees of the DalOutcomes trial and the REVEAL HPS-3 TIMI-55 trial, 2 large-scale clinical outcome trials assessing the efficacy of new cholesterylester transfer protein (CETP) inhibitors. He has published more than 300 peer-reviewed research papers on plasma lipids and lipoproteins, their metabolism, regulation, function, and relationship to atherosclerosis. He also has written handbooks on HDL and CETP inhibitors. Recognizing that atherosclerosis has become a major global epidemic, he is committed to the development of atherosclerosis research and education programs in countries beyond North America and Western Europe, including South and Southeast Asia, South and Central America, the Middle East, and Africa.

Faculty Disclosure:

Phillip J. Barter, MBBS, PhD, FRACP, has reported that he has received grant/research support from Merck and consulting fees from AstraZeneca, Kowa, Merck, Novartis, Pfizer, and Roche.